Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6048495 | 0.81 | SLC6A4 (0.45) | HTR2A | |
| SCHEMBL6771506 | 0.79 | LIPG (0.56) | TAAR1AOC3HTR2AHTR6HTR1A | |
| SCHEMBL2937482 | 0.76 | AOC3 (0.73) | TAAR1AOC3HTR2AHTR6HTR1A | |
| Hydrochloric Acid SCHEMBL8509376 | 0.74 | AOC3 (0.71) | TAAR1AOC3HTR2AHTR6SIGMAR1 | |
| SCHEMBL15479206 | 0.74 | KMT2A (0.36) | TAAR1AOC3SIGMAR1 | |
| SCHEMBL20385177 | 0.70 | IDO1 (0.36) | TAAR1SIGMAR1 | |
| SCHEMBL3064919 | 0.69 | TAAR1 (0.61) | TAAR1AOC3HTR2AHTR6HTR1A | |
| SCHEMBL3064865 | 0.69 | TAAR1 (0.61) | TAAR1AOC3HTR2AHTR6HTR1A | |
| SCHEMBL3060544 | 0.69 | TAAR1 (0.61) | TAAR1AOC3HTR2AHTR6HTR1A | |
| SCHEMBL8851121 | 0.67 | TAAR1 (0.59) | TAAR1AOC3HTR2AHTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202953-B1 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-6710080-B2 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20020198251-A1 | Substituted 2-dialkylaminoalkylbiphenyl derivatives | GRUENENTHAL GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-1202953-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010816-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198251-A1 | Substituted 2-dialkylaminoalkylbiphenyl derivatives | LIPA, PKD1, PKD2 | TAAR1 3902/4885AOC3 1118/4885HTR2A 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.